Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001230759 | SCV001403251 | uncertain significance | not provided | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with glycine at codon 493 of the ADGRV1 protein (p.Arg493Gly). The arginine residue is weakly conserved and there is a moderate physicochemical difference between arginine and glycine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with ADGRV1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV003365272 | SCV004080470 | uncertain significance | Inborn genetic diseases | 2023-07-12 | criteria provided, single submitter | clinical testing | The c.1477C>G (p.R493G) alteration is located in exon 8 (coding exon 8) of the ADGRV1 gene. This alteration results from a C to G substitution at nucleotide position 1477, causing the arginine (R) at amino acid position 493 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |